A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease inhibitor, in Japanese patients with mild-to-moderate coronavirus disease 2019 (COVID-19) or asymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukae, Hiroshi, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Imamura, Takumi, Sonoyama, Takuhiro, Fukuhara, Takahiro, Ichihashi, Genki, Sanaki, Takao, Baba, Keiko, Takeda, Yosuke, Tsuge, Yuko, Uehara, Takeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578433/
https://www.ncbi.nlm.nih.gov/pubmed/36098519
http://dx.doi.org/10.1128/aac.00697-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578433/
https://www.ncbi.nlm.nih.gov/pubmed/36098519
http://dx.doi.org/10.1128/aac.00697-22

Ejemplares similares